
Lilavati Hospital and Research Centre will open its first overseas facility in Kazakhstan in September as a super-speciality outpatient centre. The centre will offer consultations and treatment planning in oncology, cardiac sciences,…
Lilavati Hospital and Research Centre will open its first overseas facility in Kazakhstan in September as a super-speciality outpatient centre. The centre will offer consultations and treatment planning in oncology, cardiac sciences, neurology, orthopaedics, and other fields. Patients needing complex procedures or major surgeries will be referred to Lilavati’s Bandra facility in Mumbai, making the Kazakhstan centre a referral and patient-acquisition point.
The move comes as India promotes itself as a global Medical Value Travel destination. Government data shows 5.07 lakh foreign nationals came to India for medical treatment in 2025, about 5.5% of total foreign tourist arrivals. Bangladesh was the largest source market, followed by Iraq, Uzbekistan, Somalia, Turkmenistan and Oman. Lilavati plans to add about 3,000 beds over five years, including a 300-bed cancer hospital in Ahmedabad.
The medical tourism push in India is often painted as a booming industry, but numbers like 5.07 lakh foreign patients in 2025, mostly from neighbouring and conflict-affected countries, tell a story of niche demand, not mass influx. Claims of a global hub risk ignoring the high cost, regulatory hurdles, and uneven quality across private hospitals. A concrete test: will Lilavati’s Kazakhstan centre actually divert patients to Mumbai in significant numbers, or remain a showpiece?
Source: freepressjournal.in
This story was synthesised by AI from the source linked above.